Relief Therapeutics Holding AG (RLFTF)

[mc67]

"The difference between Covid-19 and a mild head cold is the ability of the Covid-19 virus to attack alveolar cells in the lung, Javitt said.

“It invades the cells and makes a million copies of itself,” he said. “It stops the production of surfaxin in the lungs, and if you can’t make surfaxin (a lubricant essential for breathing) you can’t oxygenate your blood.”

Oxygenated blood is needed for the body to function properly.

The RLF-100 polypeptide, Javitt said, has demonstrated an ability to protect the alveolar cells in the lung.

Many of the therapeutics being developed to treat respiratory distress syndrome in Covid-19 patients, he said, are designed to act like a sponge and soak up cytokines in the body. RLF-100 is being developed to block the inflammatory cytokines from being produced, he said.

“Would you rather use a sponge to mop up spilled milk, or not spill the milk in the first place?” Javitt asked. "

https://www.bizjournals.com/philadelphia/news/2020/08/27/target-covid-19-philadelphia-companies-vaccines.html